A 99-page judgment delivered on January 30, 2026, by the Honorable Supreme Court of India in the Yash Charitable Trust & Ors. v. Union of India ruled that stem cell therapy (SCT) for Autism Spectrum Disorder (ASD) cannot be offered as a routine clinical service.
The Court classified stem cells as “drugs” under the Drugs and Cosmetics Act, 1940. However, the Parents’ Forum for Stem Cells in Autism and Cerebral Palsy showed different concerns, calling out for Stem Cell Therapy to be viewed as a medical procedure rather than a manufactured drug. They also emphasized that the wait for clinical trials will stall the ongoing positive advancement seen in many children.
An interesting point of consideration is that parents weren’t given much representation, and the judgment was reached without hearing from families, who have witnessed developmental milestones in affected kids.
Currently, India is home to approximately 11.5 million children affected by developmental disabilities, with an ASD prevalence estimated at 1 in every 68 children. That is approx. 1.12% to 1.5% of children aged 2–9 yrs of age.
Drug vs Procedure
Parents view stem cell therapy as a hands-on medical intervention carried out by physicians on a case-by-case basis, rather than standardized commercial medication, thus calling it a ‘procedure’. Also, parents and clinicians should have the option to use it (with consent) if they believe it’s in the child’s best interest.
In Stem cell therapy, Minimal manipulation refers to processing that doesn’t alter the original relevant characteristics of stem cells. This excludes them from being classified as a ‘new drug’ under NDCT 2019.
However, the Court classifies all stem cells, including those minimally manipulated, as ‘substances’ intended for treatment under Section 3(b)(i) of the 1940 Act, placing them under the purview of regulatory bodies.
The Court’s Standpoint
While stem cells show promise in some areas, their use for autism remains experimental. There are still valid questions regarding its use, as there is limited solid scientific evidence that it is safe or effective, with long-term outcomes.
While the National Medical Commission (NMC) maintains that there is insufficient and inadequate scientific evidence regarding the efficacy of stem cell therapy (SCT) for treating Autism Spectrum Disorder (ASD), more than 83 peer-reviewed scientific publications from India and around the world have documented the benefits of stem cell therapy.
The NMC also stated that the ‘observed benefits’ reported by caregivers do not meet the criteria for medical validation. Contrastingly, caregivers argued that the law must uphold these ‘seen benefits’, pressing on the point that their first-hand results are substantial to be dismissed as mere anecdotal.
The Court specifically used the term ‘therapeutic misconception’ to rule that medical ethics outweighs parental and caregiver autonomy for treatments that are still being validated and clinically tested.
Parental Perspective
Parents, on the other hand, are voicing valid concerns like the hindering of vital progress due to abrupt stoppage and the delay in treatment due to a lack of infrastructure. There is considerable anxiety, as parents feel that lived experiences are now being dismissed as therapeutic misconceptions.
The Supreme Court judgment does not appear to have acknowledged the available scientific data and publications suggesting the benefits of stem cell therapy for autism.
The Logical Indian take
The Supreme Court of India’s ruling on January 30, 2026, barring stem cell therapy for children with autism outside clinical trials, marks a significant step toward prioritizing medical ethics and scientific rigor.
However, the ruling highlights a difficult balance- The imperative of ensuring safety versus the urgency associated with early developmental milestones. Acknowledging that medical care must be evidence-led, several families are demanding a framework that will include their perspectives in decision-making processes and that the ongoing treatments be continued to avoid disastrous risks for their affected children.
